Cost-effectiveness analysis of camrelizumab plus paclitaxel and carboplatin versus sintilimab plus gemcitabine and cisplatin or carboplatin for the first-line treatment of local advanced or metastatic squamous NSCLC in Chinese mainland.

MLA

Xiaoting Liu, et al. “Cost-Effectiveness Analysis of Camrelizumab plus Paclitaxel and Carboplatin versus Sintilimab plus Gemcitabine and Cisplatin or Carboplatin for the First-Line Treatment of Local Advanced or Metastatic Squamous NSCLC in Chinese Mainland.” Frontiers in Pharmacology, July 2024, pp. 1–9. EBSCOhost, https://doi.org/10.3389/fphar.2024.1356725.

APA

Xiaoting Liu, Xiao-xue Liu, Wenqing Shao, Yi Zhou, Jing Zhang, Cuirong Zhao, & Chengwu Shen. (2024). Cost-effectiveness analysis of camrelizumab plus paclitaxel and carboplatin versus sintilimab plus gemcitabine and cisplatin or carboplatin for the first-line treatment of local advanced or metastatic squamous NSCLC in Chinese mainland. Frontiers in Pharmacology, 1–9. https://doi.org/10.3389/fphar.2024.1356725

Chicago

Xiaoting Liu, Xiao-xue Liu, Wenqing Shao, Yi Zhou, Jing Zhang, Cuirong Zhao, and Chengwu Shen. 2024. “Cost-Effectiveness Analysis of Camrelizumab plus Paclitaxel and Carboplatin versus Sintilimab plus Gemcitabine and Cisplatin or Carboplatin for the First-Line Treatment of Local Advanced or Metastatic Squamous NSCLC in Chinese Mainland.” Frontiers in Pharmacology, July, 1–9. doi:10.3389/fphar.2024.1356725.